![](https://www.smart-union.org/wp-content/uploads/2015/04/DOT_Logo_150px.jpg)
On Nov. 13, 2017, the Department of Transportation (DOT) published a final rule that, among other items, expands DOT’s current drug testing panel to include certain semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). Testing for methylenedioxyethylamphetamine (MDEA) has been removed while methylenedioxyamphetamine (MDA) has been added as an initial test analyte.
The final rule also clarifies existing drug testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. The final rule becomes effective Jan. 1, 2018.
“The opioid crisis is a threat to public safety when it involves safety-sensitive employees involved in the operation of any kind of vehicle or transport,” said DOT Secretary Elaine L. Chao. “The ability to test for a broader range of opioids will advance transportation safety significantly and provide another deterrence to opioid abuse, which will better protect the public and ultimately save lives.”
Click here to read more from DOT.
Click here to read the final rule as published in the Federal Register.
Related News
- 2024 Labor Day message from TD President Jeremy Ferguson
- FRA discovers Big Orange has a big disconnect on safety
- FRA denies railroads’ request to run without watchdog technology
- SMART Railroad, Mechanical and Engineering Department reaches tentative agreements with CSX, Norfolk Southern and BNSF — ratification vote to follow
- New round of hazmat trainings announced
- Amtrak general committees announce tentative agreement
- UPDATED: Solidarity with Canadian rail workers maintained as labor situation evolves
- Retired California SLD/ASLD Michael Anderson passes away
- New tentative wage, health care agreement reached by GO 049 with CSX
- Deadline approaching for VLTD and VLIFE enrollment for rail, bus members